Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidamide + anlotinib
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chidamide + anlotinib is a combination therapy consisting of two small molecule drugs used primarily in oncology clinical trials. Chidamide (also known as tucidinostat) is a selective histone deacetylase (HDAC) inhibitor that modulates gene expression and has demonstrated antitumor activity by inducing cell cycle arrest, apoptosis, and enhancing immune response. Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits angiogenesis and tumor cell proliferation by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. The combination aims to leverage the epigenetic modulation of chidamide with the anti-angiogenic and antiproliferative effects of anlotinib for synergistic antitumor efficacy. This regimen has been investigated in phase II clinical studies for advanced or recurrent cancers including pancreatic cancer and HER2-low breast cancer[1][3][7].
- Other names
- tucidinostat + anlotinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC11 (Histone Deacetylase 11)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC8 (Histone Deacetylase 8)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)MYC (MYC proto-oncogene protein)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)FGFR (FGFR family)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on chidamide + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidamide + anlotinib.